Skip to content

Anna O. Ermakova

12 papers in the library · 148 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network

Frontiers in Psychiatry October 14, 2026 Mathieu Seynaeve, Leonie Schneider, Ian Roullier et al.

BackgroundWhile psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.MethodsThis qualitative descriptive study, informed...

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction August 3, 2026 Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova et al.

BACKGROUND AND AIMS: This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural...

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Journal of Psychopharmacology February 27, 2026 Claire T. Roberts, Mathieu Seynaeve, Anna O. Ermakova et al.

Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.

5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction December 10, 2025 John Marsden, Michael Kelleher, Fiona Dunbar et al. 2 citations

Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT). Design Open‐label,...

DOI: 10.1111/add.70260 (opens in new tab) Alcohol use disorder Tolerability Craving Clinical trial +4

Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.

Scientific Reports November 6, 2025 Anna O. Ermakova, Fiona Dunbar, Mathieu Seynaeve et al. 3 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring psychedelic tryptamine. Plants containing 5-MeO-DMT have been used throughout history, and in recent years both synthetic and toad-derived 5-MeO-DMT use is being increasingly reported in naturalistic settings as well as clinical research. However, its subjective effects are not well characterised, and no qualitative research...

Of shrub, cactus, vine and toad: psychedelic species of conservation concern

Frontiers in Conservation Science September 29, 2025 Anna O. Ermakova, Sam Gandy

Psychedelics have a profound potential to catalyze psychological transformation and support traditional cultures and ways of life. However, many naturally occurring psychoactive plants and animals are facing threats from climate change, habitat loss and other anthropogenic pressures like overharvesting. In this narrative review we examine the conservation issues pertaining to some of the most...

DOI: 10.3389/fcosc.2025.1569528 (opens in new tab) Traditional knowledge Indigenous Sustainability Vine +12

O relatório da DEA sobre os riscos da ayahuasca: a “ciência” a serviço do proibicionismo?

Ponto Urbe December 27, 2024 Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.

Em fevereiro de 2023, a Drug Enforcement Administration (DEA) divulgou um documento para a equipe jurídica que representa a Church of the Eagle and the Condor (“CEC”). Essa divulgação ocorreu dois anos depois que a igreja, em conjunto com o Chacruna Institute, enviou duas solicitações baseadas na lei de liberdade de informação [Freedom Of Information Act] à DEA e ao Departamento de Justiça...

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of Psychopharmacology August 1, 2024 James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al. 32 citations

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...

Indigenous psilocybin mushroom practices: An annotated bibliography

Journal of Psychedelic Studies February 19, 2024 Nicholas Spiers, Beatriz Caiuby Labate, Anna O. Ermakova et al. 27 citations

Abstract This annotated bibliography comprises 49 texts concerning psilocybin mushroom practices developed by Indigenous peoples. The books and articles have been selected for their academic rigor, relevance, and historical significance, and to foreground overlooked research and subject matter. This includes research on a plurality of contemporary practices and evidence of historical uses, from...

DOI: 10.1556/2054.2023.00297 (opens in new tab) Full text (opens in new tab) Psilocybin Indigenous Contextualization Annotated bibliography +6

The DEA report on ayahuasca risks: “Science” in service of prohibition?

Journal of Psychedelic Studies June 9, 2023 Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al. 1 citation

Abstract On February 2023, the Drug Enforcement Administration (DEA) released a document to the legal team representing the Church of the Eagle and the Condor (“CEC”). This disclosure came two years after the church, in conjunction with Chacruna Institute, submitted two FOIA requests to the DEA and the Department of Justice requesting all records pertaining to ayahuasca. This report, titled...

A narrative synthesis of research with 5-MeO-DMT.

Journal of Psychopharmacology March 1, 2022 Anna O. Ermakova, Fiona Dunbar, James Rucker et al. 83 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine, produced by a variety of plant and animal species. Plants containing 5-MeO-DMT have been used throughout history for ritual and spiritual purposes. The aim of this article is to review the available literature about 5-MeO-DMT and inform subsequent clinical development. We searched PubMed...